Skip to main content
. 2021 Jan 5;20:199–208. doi: 10.1016/j.omto.2020.12.013

Table 3.

Stratification analysis between YTHDC1 genotypes and glioma risk

Variables rs2293595 AOR (95% CI)a pa rs3813832 AOR (95% CI)a pa Protective genotypesb AOR (95% CI)a pa
(cases/controls) (cases/controls) (cases/controls)
TT TC/CC TT TC/CC 0–1 2–3
Age, months
<60 34/40 51/79 0.76 (0.43–1.35) 0.348 51/58 34/61 0.63 (0.36–1.11) 0.111 45/53 40/66 0.71 (0.4–1.24) 0.229
≥60 43/34 43/75 0.46 (0.25–0.82)c 0.009c 58/57 28/52 0.55 (0.30–0.99)c 0.044c 55/48 31/61 0.46 (0.26–0.82)c 0.008c
Gender
Females 40/27 41/66 0.42 (0.22–0.80)c 0.008c 56/46 25/47 0.47 (0.25–0.88)c 0.018c 52/39 29/54 0.44 (0.24–0.82)c 0.010c
Males 37/47 53/88 0.77 (0.44–1.34) 0.358 53/69 37/66 0.74 (0.43–1.27) 0.275 48/62 42/73 0.74 (0.43–1.27) 0.271
Subtypes
Astrocytic tumors 59/74 66/154 0.54 (0.34–0.86)c 0.009c 83/115 42/113 0.54 (0.34–0.86)c 0.009c 76/101 49/127 0.53 (0.34–0.84)c 0.007c
Ependymoma 10/74 15/154 0.76 (0.32–1.78) 0.520 14/115 11/113 0.77 (0.33–1.79) 0.546 12/101 13/127 0.87 (0.38–2.01) 0.744
Neuronal and mixed 6/74 8/154 0.68 (0.22–2.04) 0.489 7/115 7/113 1.01 (0.34–3.00) 0.984 7/101 7/127 0.83 (0.28–2.46) 0.732
Embryonal tumors 2/74 5/154 0.80 (0.13–4.84) 0.806 5/115 2/113 0.48 (0.08–2.85) 0.415 5/101 2/127 0.36 (0.06–2.15) 0.264
Tumor grades
I 46/74 57/154 0.60 (0.37–0.97)c 0.037c 63/115 40/113 0.68 (0.42–1.10) 0.112 59/101 44/127 0.61 (0.38–0.98)c 0.042c
II 15/74 13/154 0.42 (0.19–0.92)c 0.031c 21/115 7/113 0.34 (0.14–0.83)c 0.017c 19/101 9/127 0.38 (0.16–0.87)c 0.022c
III 6/74 9/154 0.74 (0.25–2.17) 0.577 8/115 7/113 0.86 (0.30–2.47) 0.777 7/101 8/127 0.91 (0.32–2.62) 0.859
IV 10/74 15/154 0.72 (0.29–1.78) 0.479 17/115 8/113 0.58 (0.23–1.47) 0.250 15/101 10/127 0.66 (0.27–1.61) 0.355
I+II 61/74 70/154 0.55 (0.35–0.86)c 0.009c 84/115 47/113 0.59 (0.38–0.92)c 0.019c 78/101 53/127 0.55 (0.36–0.85)c 0.008c
III+IV 16/74 24/154 0.73 (0.36–1.47) 0.377 25/115 15/113 0.67 (0.33–1.36) 0.265 22/101 18/127 0.72 (0.36–1.43) 0.342

AOR, adjusted odds ratio; CI, confidence interval.

a

Adjusted for age and gender, omitting the corresponding stratify factor.

b

Protective genotypes were carriers with rs2293596 TC/CC, rs2293595 TC/CC, and rs3813832 TC/CC genotypes.

c

Significant results.